{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:36Z","timestamp":1786358316785,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.ahj.2004.04.036","type":"journal-article","created":{"date-parts":[[2004,11,8]],"date-time":"2004-11-08T13:44:05Z","timestamp":1099921445000},"page":"764-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"title":["Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale"],"prefix":"10.1016","volume":"148","author":[{"given":"Gregg W.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Lansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2004.04.036_BIB1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0140-6736(99)07349-3","article-title":"Invasive compared with non-invasive treatment in unstable coronary-artery disease","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.04.036_BIB3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(02)09894-X","article-title":"Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction","volume":"360","author":"Fox","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.04.036_BIB4","doi-asserted-by":"crossref","first-page":"96S","DOI":"10.1016\/S0735-1097(02)02688-8","article-title":"\u201cIschemia-guided\u201d versus \u201cearly invasive\u201d strategies in the management of acute coronary syndrome\/non\u2013ST-segment elevation myocardial infarction: the interventionalist's perspective","volume":"41","author":"McKay","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB5","doi-asserted-by":"crossref","first-page":"113S","DOI":"10.1016\/S0735-1097(02)02963-7","article-title":"\u201cRoutine invasive\u201d versus \u201cselective invasive\u201d approaches to non\u2013ST-segment elevation acute coronary syndromes management in the post-stent\/platelet inhibition era","volume":"41","author":"Boden","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","article-title":"ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.04.036_BIB9","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.04.036_BIB10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non\u2013Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.04.036_BIB13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB14","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB15","unstructured":"Braunwald E, Antman EM, Beasley JW, et al. ACC\/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. http:\/\/www.acc.org\/clinical\/guidelines\/unstable\/update_explantext.htm"},{"key":"10.1016\/j.ahj.2004.04.036_BIB16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.0000037106.76139.53","article-title":"ACC\/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction \u20142002: summary article","volume":"106","author":"Braunwald","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJM200206063462313","article-title":"When increased therapeutic benefit comes at increased cost","volume":"346","author":"Wood","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB18","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jama.288.15.1851","article-title":"Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction","volume":"288","author":"Mahoney","year":"2002","journal-title":"JAMA"},{"issue":"suppl B","key":"10.1016\/j.ahj.2004.04.036_BIB19","first-page":"48B","article-title":"Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention","volume":"14","author":"Aguirre","year":"2002","journal-title":"J Invasive Cardiol"},{"issue":"suppl 3","key":"10.1016\/j.ahj.2004.04.036_BIB20","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/ajhp\/60.suppl_3.S15","article-title":"Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention","volume":"60","author":"Milkovich","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ahj.2004.04.036_BIB21","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2004.04.036_BIB22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-8588(18)30515-X","article-title":"Heparin and platelets","volume":"4","author":"Warkentin","year":"1990","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ahj.2004.04.036_BIB24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/107424849800300201","article-title":"Therapeutic concentrations of heparin augment platelet activation at the time of coronary angiography","volume":"3","author":"Naqvi","year":"1998","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2004.04.036_BIB25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.1989.tb00290.x","article-title":"The mechanism of heparin-induced platelet aggregation","volume":"43","author":"Chong","year":"1989","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB26","first-page":"358","article-title":"The influence of heparin and protamine sulfate on platelet ADP and platelet factor-4 release and the expression of glycoprotein IIb\/IIIa","volume":"24","author":"Storck","year":"1994","journal-title":"Haemostasis"},{"key":"10.1016\/j.ahj.2004.04.036_BIB27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1067\/mva.2001.112696","article-title":"Heparin modulates integrin function in human platelets","volume":"33","author":"Sobel","year":"2001","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2004.04.036_BIB29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.CIR.104.2.181","article-title":"Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention","volume":"104","author":"Kabbani","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin-III: independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2004.04.036_BIB31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/01.CIR.97.6.544","article-title":"Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors","volume":"97","author":"Weitz","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB32","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1074\/jbc.274.10.6226","article-title":"Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II","volume":"274","author":"Becker","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2004.04.036_BIB33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0167-4889(85)90177-6","article-title":"Binding and endocytosis of heparin by human endothelial cells in culture","volume":"845","author":"Barzu","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ahj.2004.04.036_BIB34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2004.04.036_BIB35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1055\/s-0037-1616529","article-title":"Human thrombi contain an abundance of active thrombin","volume":"86","author":"Mutch","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2004.04.036_BIB37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/01.CIR.93.2.253","article-title":"Coronary thrombi increase PTCA risk","volume":"93","author":"White","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB38","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000077530.53367.E9","article-title":"Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"issue":"4 suppl S","key":"10.1016\/j.ahj.2004.04.036_BIB39","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1016\/S0735-1097(02)02901-7","article-title":"The role of low-molecular-weight heparin in the management of acute coronary syndromes","volume":"41","author":"Cohen","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"4 suppl S","key":"10.1016\/j.ahj.2004.04.036_BIB40","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1016\/S0735-1097(02)02687-6","article-title":"The evolving role of direct thrombin inhibitors in acute coronary syndromes","volume":"41","author":"Eikelboom","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"suppl F","key":"10.1016\/j.ahj.2004.04.036_BIB41","first-page":"20F","article-title":"Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions","volume":"12","author":"Kleiman","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB42","unstructured":"Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost 1999;(suppl 3):57\u201361"},{"key":"10.1016\/j.ahj.2004.04.036_BIB43","unstructured":"Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990;(suppl 16):12\u20138"},{"key":"10.1016\/j.ahj.2004.04.036_BIB44","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1046\/j.1538-7836.2003.00254.x","article-title":"Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex","volume":"1","author":"Brufatto","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2004.04.036_BIB45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0735-1097(03)01053-2","article-title":"A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention","volume":"42","author":"Moliterno","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non\u2013ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1067\/mhj.2001.116959","article-title":"The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular weight heparin with the glycoprotein IIb\/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy","volume":"142","author":"Blazing","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB50","doi-asserted-by":"crossref","unstructured":"Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractured heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55\u201364","DOI":"10.1001\/jama.292.1.55"},{"issue":"suppl E","key":"10.1016\/j.ahj.2004.04.036_BIB51","first-page":"E14","article-title":"Low-molecular-weight heparin therapy in percutaneous coronary intervention","volume":"12","author":"Young","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB52","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB53","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0002-8703(02)00131-X","article-title":"Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus","volume":"144","author":"Kereiakes","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB54","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.04.036_BIB55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-0037-1615780","article-title":"Biochemistry and physiology of blood coagulation","volume":"82","author":"Mann","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2004.04.036_BIB56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","article-title":"Thrombin functions during tissue factor\u2013induced blood coagulation release and factor XIII activation","volume":"100","author":"Brummel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2004.04.036_BIB57","series-title":"Hemostasis and Thrombosis","first-page":"505","article-title":"Platelet stimulatory and inhibitory receptors","author":"Ashby","year":"2001"},{"key":"10.1016\/j.ahj.2004.04.036_BIB58","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB59","series-title":"Hemostasis and Thrombosis","first-page":"3","article-title":"Overview of hemostasis","author":"Colman","year":"2001"},{"key":"10.1016\/j.ahj.2004.04.036_BIB60","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB61","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.04.036_BIB62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1385\/CT:3:1:13","article-title":"Direct thrombin inhibitors in cardiac disease","volume":"3","author":"Weitz","year":"2003","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00019501-199606000-00006","article-title":"Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes","volume":"7","author":"Maraganore","year":"1996","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ahj.2004.04.036_BIB64","unstructured":"Henry TD. Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy: replacing heparin with bivalirudin. J Invasive Cardiol 2002;(14 suppl B):19B\u201329B"},{"key":"10.1016\/j.ahj.2004.04.036_BIB65","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.04.036_BIB66","doi-asserted-by":"crossref","first-page":"43P","DOI":"10.1016\/S0002-9149(98)00766-8","article-title":"A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina","volume":"82","author":"Bittl","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.04.036_BIB67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.CIR.92.4.727","article-title":"Hirulog in the treatment of unstable angina","volume":"92","author":"Fuchs","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mhj.2002.120405","article-title":"Bivalirudin as a replacement for unfractionated heparin in unstable angina\/non-ST-elevation myocardial infarction","volume":"143","author":"Antman","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB69","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","article-title":"Clinical outcomes of bivalirudin for ischemic heart disease","volume":"100","author":"Kong","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.04.036_BIB70","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0002-8703(03)00517-9","article-title":"A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes","volume":"146","author":"Roe","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.04.036_BIB71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.ahj.2004.04.036_BIB72","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304002819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304002819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:11:32Z","timestamp":1757567492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870304002819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0002870304002819"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2004.04.036","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2004.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}